Ask The Experts: The Evolution of Immune Checkpoint Inhibitors to Treat Lung Cancer and Melanoma

Immune checkpoint inhibition continues to evolve as standard therapy for a growing number of solid and hematologic malignancies including melanoma and lung cancer. This educational activity will discuss the pathophysiology and evolution of immune checkpoint inhibitors and analyze recent survival and toxicity data for managing patients with melanoma and lung cancer. Additionally, identification of biomarkers to optimize immune checkpoint inhibitor selection will be explored.

Target Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of lung cancer and melanoma patients with immunotherapies.

Learning Objectives

  • Define the pathophysiology of immunotherapy and the evolution of immune checkpoint inhibition.
  • Analyze recent immune checkpoint inhibitor survival and toxicity data and apply to the therapy management of patients with melanoma and lung cancer.
  • Identify established and emerging biomarkers to optimize selection of immune checkpoint regimens for patients with melanoma and lung cancer.
  • Describe interprofessional education strategies for patients and caregivers on the safety and monitoring of immune checkpoint inhibitors.

Additional Information

Partner: 
myCME
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
05/13/2020
Course expires: 
05/13/2021
Rating: 
0

Christine M. Walko, Pharm.D., BCOP, FCCP, Activity Chair
Associate Member, Department of Individualized Cancer Management
Moffitt Cancer Center
Tampa, Florida

Dr. Walko discloses the following: Consultant: Jackson Genetic Laboratories.

Shetal Patel, M.D., Ph.D.
Assistant Professor of Medicine
Division of Hematology/Oncology
UNC School of Medicine
Chapel Hill, North Carolina

Dr. Patel discloses the following: Principle Investigator: AstraZeneca

Commercial Supporter

Supported by independent educational grants from Bristol-Myers Squibb and Merck.

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.

Conflict of Interest Disclosure Policy

Planners, presenters, reviewers, ASHP staff, and others with an opportunity to control CE content are required to disclose relevant financial relationships with ACCME-defined commercial interests. All actual conflicts of interest have been resolved prior to the continuing education activity taking place. ASHP will disclose financial relationship information prior to the beginning of the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

AMA PRA Category 1 Credit TM

Accreditation Statement
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy Credits

Pharmacists may earn 1.00 CPE credits (0.10 CEUs) by creating a free account and completing this course at elearning.ashp.org. Your certificate will save on elearning.ashp.org and will not be included in your myCME Dashboard. CPE will be reported directly to CPE Monitor (be prepared to provide your NABP eProfile ID and birth month and date and to claim CE within 60 days of completion).

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through MyCME. To take this course you will be redirected to MyCME's website. You must have an account with MyCME in order to complete this activity. 

MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!